Related Experiment Video

Updated: Jan 23, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

2.0K

Integrative Approach to Pediatric Nausea

Jenna Arruda, Ann Ming Yeh

    Pediatric Annals
    |June 12, 2019
    PubMed

    More Related Videos

    An Integrated Approach for Microprotein Identification and Sequence Analysis09:37

    An Integrated Approach for Microprotein Identification and Sequence Analysis

    Published on: July 12, 2022

    4.0K
    Guidelines for Elective Pediatric Fiberoptic Intubation11:19

    Guidelines for Elective Pediatric Fiberoptic Intubation

    Published on: January 17, 2011

    18.4K

    Related Concept Videos

    Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

    Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

    Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
    Two synthetic agonists of THC,...
    712
    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

    5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
    618
    Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

    Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

    Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
    Phenothiazines, such as prochlorperazine...
    831
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    214
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
    271
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    199